GSK/Corixa Bexxar gets review

GlaxoSmithKline/Corixa's BLA (125011/0) for Bexxar in the treatment of non-Hodgkin's lymphoma will be reviewed by FDA's Oncologic Drugs Advisory Committee on Dec. 17. The companies requested a meeting after receiving a March "complete review" letter from FDA (1"The Pink Sheet" May 20, In Brief). The meeting will begin at 12:30 p.m. at the Holiday Inn in Bethesda, Md. [Editor's note: To view a 2webcast/video of this and other advisory committee meetings, go to FDAAdvisoryCommittee.com]...